Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients

• Main Authors: Heriberto Bruzzoni-Giovanelli (Author), Habib Zouali (Author), Mourad Sahbatou (Author), Benjamin Maneglier (Author), Jean-Michel Cayuela (Author), Angelita Rebollo (Author), Gustavo H. Marin (Author), Daniela Geromin (Author), Carole Tomczak (Author), Antonio Alberdi (Author), Jean-Francois Deleuze (Author), Philippe Rousselot (Author)
• Format: Bog
• Udgivet: MDPI AG, 2024-06-01T00:00:00Z.
• Fag: article
• Online adgang: Connect to this object online.

The tyrosine kinase Inhibitor (TKI) imatinib is approved for the treatment of the chronic phase of chronic myeloid leukemia (CP-CML). Pharmacokinetic studies have highlighted the importance of inter-patient variability on imatinib plasma trough concentrations (ima[C]min). In the OPTIM-imatinib trial...